Company AbbVie and Sosei concluded an agreement on joint development of drugs, the cost of which may reach $ 1 billion, writes Reuters.
The parties will work together to conduct research and commercialize drugs specific to the receptors associated with G-protein (GPCR). As a down payment to Sosei will receive $ 32 million, together with subsequent payments and royalties from sales total amount of payments could reach $ 1 billion. AbbVie will also have the opportunity to expand cooperation and development of the four candidate drugs.
The development of similar drugs with Sosei cooperate with Genentech, and Takeda.